Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
XGN 
Exagen Inc (XGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/24/2025: XGN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -41.29% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 70.34M USD | Price to earnings Ratio - | 1Y Target Price 6.75 |
Price to earnings Ratio - | 1Y Target Price 6.75 | ||
Volume (30-day avg) 85533 | Beta 1.4 | 52 Weeks Range 1.30 - 6.22 | Updated Date 04/1/2025 |
52 Weeks Range 1.30 - 6.22 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.83 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-17 | When Before Market | Estimate -0.24 | Actual -0.2 |
Profitability
Profit Margin -27.17% | Operating Margin (TTM) -24.78% |
Management Effectiveness
Return on Assets (TTM) -16.77% | Return on Equity (TTM) -93.78% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 65223171 | Price to Sales(TTM) 1.26 |
Enterprise Value 65223171 | Price to Sales(TTM) 1.26 | ||
Enterprise Value to Revenue 1.17 | Enterprise Value to EBITDA -0.16 | Shares Outstanding 17898100 | Shares Floating 9317571 |
Shares Outstanding 17898100 | Shares Floating 9317571 | ||
Percent Insiders 25.69 | Percent Institutions 54.24 |
Analyst Ratings
Rating 4.67 | Target Price 6.75 | Buy - | Strong Buy 5 |
Buy - | Strong Buy 5 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Exagen Inc
Company Overview
History and Background
Exagen Inc. was founded in 2002. It is a commercial-stage diagnostics company focused on transforming the care of patients with autoimmune diseases. The company has focused on autoimmune testing and building a strong commercial infrastructure to drive adoption of its products.
Core Business Areas
- Rheumatology Diagnostics: Exagen's core business is centered around providing diagnostic and monitoring solutions for rheumatology, specifically targeting patients with autoimmune disorders.
- Avise Testing: The company's Avise testing platform offers a range of blood-based tests designed to aid in the diagnosis, prognosis, and monitoring of autoimmune diseases like rheumatoid arthritis, lupus, and systemic sclerosis.
Leadership and Structure
Exagen's leadership team consists of seasoned executives with experience in diagnostics, healthcare, and commercial operations. The organizational structure reflects a functional model, with departments dedicated to research and development, commercial operations, finance, and administration.
Top Products and Market Share
Key Offerings
- Avise MTX: Avise MTX is a test designed to monitor patients on methotrexate therapy, predicting response and optimizing treatment. Competitors include Prometheus Laboratories (now part of Nestle Health Science). While exact market share is difficult to pin down precisely, Exagen is a major player in autoimmune diagnostic testing, especially rheumatology.
- Avise Lupus: Avise Lupus is a diagnostic test for systemic lupus erythematosus (SLE). It provides a more comprehensive assessment than traditional tests. Competitors include companies offering traditional lupus tests as well as other specialized autoimmune testing companies like Labcorp (LH) and Quest Diagnostics (DGX). Market share data is not publicly disclosed, but Avise Lupus represents a significant portion of Exagen's revenue.
- Avise SLE Monitor: A blood test to monitor disease activity in individuals with systemic lupus erythematosus (SLE). It aids in the diagnosis, prognosis, and monitoring of autoimmune diseases. The market consists of other lupus diagnostics and monitoring tests offered by companies such as Labcorp and Quest Diagnostics. Revenue data is not broken out by product but makes up a part of the total revenue.
Market Dynamics
Industry Overview
The autoimmune disease diagnostics market is growing, driven by increasing prevalence of autoimmune disorders, advances in biomarker technology, and a greater emphasis on personalized medicine. The market is highly competitive, with numerous companies offering various diagnostic solutions.
Positioning
Exagen is positioned as a leader in rheumatology diagnostics, particularly for complex autoimmune diseases. Its Avise platform offers differentiated testing capabilities, giving it a competitive advantage in the market. Their competitive advantages are their differentiated products and specialization in niche markets.
Total Addressable Market (TAM)
The total addressable market is estimated to be in the billions of dollars, considering the prevalence of autoimmune diseases. Exagen is focused on capturing a significant share of this market through its innovative diagnostic solutions.
Upturn SWOT Analysis
Strengths
- Differentiated Avise testing platform
- Strong focus on rheumatology diagnostics
- Established commercial infrastructure
- Proprietary biomarkers and technology
- Strong expertise in autoimmune diseases
Weaknesses
- Reliance on reimbursement policies
- Concentration of revenue in a few key tests
- Relatively small size compared to larger diagnostic players
- Profitability Challenges
Opportunities
- Expanding into new autoimmune disease areas
- Developing new diagnostic and monitoring tests
- Partnerships with pharmaceutical companies
- Geographic expansion
- Increased awareness of autoimmune diseases
Threats
- Changes in reimbursement policies
- Competition from larger diagnostic companies
- Development of competing technologies
- Regulatory hurdles
- Economic downturns
Competitors and Market Share
Key Competitors
- LH
- DGX
- CSTL
- SQNM
Competitive Landscape
Exagen's competitive advantage lies in its differentiated Avise platform and focus on rheumatology diagnostics. However, it faces competition from larger, more diversified diagnostic companies with greater resources.
Major Acquisitions
Predictive Biomarkers Laboratory
- Year: 2019
- Acquisition Price (USD millions): 13
- Strategic Rationale: Expanded Exagen's IP portfolio and strengthened their offering of biomarkers for autoimmune diseases.
Growth Trajectory and Initiatives
Historical Growth: Exagen has demonstrated revenue growth driven by adoption of its Avise testing platform. However, profitability has been a challenge.
Future Projections: Future growth projections depend on various conditions, including expansion into new market segments, regulatory approvals, and changes in market demand. Analyst forecasts are needed to get an accurate outlook.
Recent Initiatives: Recent initiatives include expanding the Avise test menu, securing partnerships with pharmaceutical companies, and increasing commercialization efforts.
Summary
Exagen Inc. is a growing company focused on autoimmune disease diagnostics, particularly in rheumatology. Its innovative Avise platform and strong commercial infrastructure are working well, driving revenue growth. However, profitability and competition from larger diagnostic companies remain challenges. Exagen needs to focus on managing costs and expanding its product offerings to sustain long-term growth.
Similar Companies
CSTL
Castle Biosciences Inc
CSTL
Castle Biosciences Inc
DGX
Quest Diagnostics Incorporated
DGX
Quest Diagnostics Incorporated
ILMN
Illumina Inc
ILMN
Illumina Inc
LH
Laboratory Corporation of America Holdings
LH
Laboratory Corporation of America Holdings
TMO
Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Data is based on publicly available information and may not be entirely accurate or up-to-date. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Exagen Inc
Exchange NASDAQ | Headquaters Vista, CA, United States | ||
IPO Launch date 2019-09-19 | CEO, President & Director Mr. John Aballi | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 209 | Website https://www.exagen.com |
Full time employees 209 | Website https://www.exagen.com | ||
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.